Daniel J. Schaid

Daniel J. Schaid

Auto-generated profile, based on publicly available information

Daniel J. Schaid

Department of Quantitative Health Sciences, Mayo Clinic, Rochester, USA

Research Focus & Metrics

Academic Career Length

35Years (1992-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 February 2002 in The American Journal of Human Genetics
Verified
Journal Article
Closed access
DSDaniel J. Schaid
Daniel J. Schaid
CRCharles M. Rowland
Charles M. Rowland
DTDavid E. Tines
David E. Tines
RJRobert Martin Jacobson
Robert Martin Jacobson
GPGregory A. Poland
Gregory A. Poland

29 May 2018 in Nature Reviews Genetics
Verified
Journal Article
Closed access
PDF file
DSDaniel J. Schaid
Daniel J. Schaid
WCWenan Chen
Wenan Chen
Nicholas B LarsonNicholas B Larson
Nicholas B Larson

13 January 2004 in Human Molecular Genetics
Verified
Journal Article
Open access
PDF file
DSDaniel J. Schaid
Daniel J. Schaid
Prostate cancer is the most frequent cancer among men in most developed countries, yet little is known about its causes. Older age, African ancestry and a positive family history of prostate cancer have long been recognized as important risk factors. The evidence that genetics probably plays a critical role is based on a variety of study designs, including case–control, cohort, twin and family-based, all of which are reviewed in detail. The search for prostate cancer susceptibility genes by linkage studies offered early hope that finding genes would be as ‘easy’ as finding genes for breast cancer and colon cancer susceptibilities. However, this hope has been dampened by the difficulty of replicating promising regions of linkage. This review provides updates on recent developments, and a broad view of the disparate findings from different linkage studies. Early linkage results have provided targeted candidate regions for prostate cancer susceptibility loci, including HPC1 on chromosome 1q23–25, PCAP on chromosome 1q42–43, CAPB on chromosome 1p36, linkage to chromosome 8p22–23, HPC2 on chromosome 17p, HPC20 on chromosome 20q13, and HPCX on chromosome Xq27–28. These linkage findings lead to refined mapping and mutation screening of several strong candidate genes, including ELAC2, RNASEL and MSR1. Up to now, a total of 10 genome-wide linkage scans for prostate cancer susceptibility have been completed, and are reviewed. Furthermore, recent findings that Gleason's grade, a measure of aggressiveness of prostate cancer, is linked to several genomic regions are reviewed. Finally, the roles of environmental and dietary risk factors, and common genetic polymorphisms of genes likely to play a role in common forms of prostate cancer, are briefly discussed within in the context of searching for genes that influence prostate cancer risk.

12 November 2004 in Genetic Epidemiology
Verified
Journal Article
Closed access
PDF file
DSDaniel J. Schaid
Daniel J. Schaid

6 May 2015 in Genetics
Verified
Journal Article
Open access
PDF file
WCWenan Chen
Wenan Chen
BLBeth R. Larrabee
Beth R. Larrabee
IOInna G. Ovsyannikova
Inna G. Ovsyannikova
RKRichard B. Kennedy
Richard B. Kennedy
IHIana H. Haralambieva
Iana H. Haralambieva
DSDaniel J. Schaid
Daniel J. Schaid
Two recently developed fine-mapping methods, CAVIAR and PAINTOR, demonstrate better performance over other fine-mapping methods. They also have the advantage of using only the marginal test statistics and the correlation among SNPs. Both methods leverage the fact that the marginal test statistics asymptotically follow a multivariate normal distribution and are likelihood based. However, their relationship with Bayesian fine mapping, such as BIMBAM, is not clear. In this study, we first show that CAVIAR and BIMBAM are actually approximately equivalent to each other. This leads to a fine-mapping method using marginal test statistics in the Bayesian framework, which we call CAVIAR Bayes factor (CAVIARBF). Another advantage of the Bayesian framework is that it can answer both association and fine-mapping questions. We also used simulations to compare CAVIARBF with other methods under different numbers of causal variants. The results showed that both CAVIARBF and BIMBAM have better performance than PAINTOR and other methods. Compared to BIMBAM, CAVIARBF has the advantage of using only marginal test statistics and takes about one-quarter to one-fifth of the running time. We applied different methods on two independent cohorts of the same phenotype. Results showed that CAVIARBF, BIMBAM, and PAINTOR selected the same top 3 SNPs; however, CAVIARBF and BIMBAM had better consistency in selecting the top 10 ranked SNPs between the two cohorts. Software is available at https://bitbucket.org/Wenan/caviarbf.

1 October 2001 in Journal of Clinical Oncology
Verified
Journal Article
Closed access
SMShannon K. McDonnell
Shannon K. McDonnell
DSDaniel J. Schaid
Daniel J. Schaid
JMJeffrey L. Myers
Jeffrey L. Myers
CGClive S. Grant
Clive S. Grant
JDJohn H. Donohue
John H. Donohue
LHLynn C. Hartmann
Lynn C. Hartmann
PURPOSE: To estimate the efficacy of contralateral prophylactic mastectomy in women with a personal and family history of breast cancer. PATIENTS AND METHODS: We followed the course of 745 women with a first breast cancer and a family history of breast and/or ovarian cancer who underwent contralateral prophylactic mastectomy at the Mayo Clinic between 1960 and 1993. Family history information and cancer follow-up information were obtained from the medical record, a study-specific questionnaire, and telephone follow-up. Life-tables for contralateral breast cancers, which consider age at first breast cancer, current age, and type of family history, were used to calculate the number of breast cancers expected in our cohort had they not had a prophylactic mastectomy. RESULTS: Of the 745 women in our cohort, 388 were premenopausal (age < 50 years) and 357 were post- menopausal. Eight women developed a contralateral breast cancer. Six events were observed among the premenopausal women, compared with 106.2 predicted, resulting in a risk reduction of 94.4% (95% confidence interval [CI], 87.7% to 97.9%). For the 357 postmenopausal women, 50.3 contralateral breast cancers were predicted, whereas only two were observed, representing a 96.0% risk reduction (95% CI, 85.6% to 99.5%). CONCLUSION: The incidence of contralateral breast cancer seems to be reduced significantly after contralateral prophylactic mastectomy in women with a personal and family history of breast cancer.